Filter posts

First Zika Vaccine Ready for Human Trials

Earlier this week, we learned a welcome piece of good news in the ongoing Zika …

ICYMI: The Hill Op-Ed on Ending 340B Abuse

Writing in The Hill today, Ellen Weaver of the Palmetto Promise Institute and Lindsay Boyd …

CDC’s Frieden: Private Sector Stepping up to Combat Zika, Congress Should Too

Writing at the White House blog, CDC Director Dr. Tom Frieden says his colleagues working …

Biotech Solutions for Zika

The Zika virus epidemic continues to rage on. Just today, the WHO advised people in Zika affected …

Strategic Venture Investing by Large Pharma: Is “Smart Money” Right for Your Company

The strategic venture arms of major biopharma companies like AbbVie, Amgen, Johnson & Johnson and …

Yoshinori Ohsumi, Ph.D., Receives 2016 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson presented cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology, …

Nailed It! Rock Star Panel

Today’s “Nailed It! Rock Star Panel,” sponsored by Johnson & Johnson Innovation/JLABS, featured three company …

Curative Therapies: Aligning Policy with Science to Ensure Patient Access

New hepatitis C medications with exceptionally high cure rates have significantly improved treatment, while also …

Facts Not Fiction: Digital Delivers Results for Biotech Companies

A panel of experts in the digital advertising space assembled Wednesday at the 2016 BIO International …

Antibiotic Development Incentives May Be Tricky to Implement

A recently proposed broad suite of antibiotic development incentives has received strong support from industry …